Iris Unimi Prodmetadata only
Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial
frontline therapy, non-small-cell lung cancer, pralsetinib, ret fusion, ret inhibition, targeted therapy, settore meds-09/a - oncologia medica
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 274667
Conceptio Open Knowledge Archive — every document is proof-bundled with source, license, and retrieval metadata.